ABO Blood Type and the Long-term Outcomes of Pancreatic Cancer
ABO Blood Type and the Long-term Outcomes of Pancreatic Cancer
复制标题
DOI：
10.2169/internalmedicine.3748-19
复制
发表时间：
2020-01-01
影响因子：
1.2
通讯作者：
Hiasa, Yoichi
中科院分区：
文献类型：
--
作者：
Tanaka, Yoshinori;Kumagi, Teru;Hiasa, Yoichi
目的ABO血型对胰腺癌（PC）患者临床病程的长期影响尚无定论。本研究旨在确定ABO血型是否影响PC的长期结果在日本patients.Methods与PC的日本患者的病历进行了审查。对爱媛县胰腺-胆管病学研究小组的数据（包括年龄、性别和结局）进行了分析。结果406名患者的平均年龄为71.0 ± 10.5岁，其中220名（54.2%）为男性。A型、B型、O型和AB型分别占44.6%、20.7%、22.4%和12.3%。携带A等位基因的患者的中位生存时间（MST）短于携带非A等位基因的患者（p=0.048），尤其是在接受切除术的患者中（p=0.031）。相比之下，在接受化疗和姑息治疗的患者中，MST没有显著差异。最后，多因素分析证实A等位基因是与PC长期预后相关的独立因素（p
Objective The long-term effect of the ABO blood type on the clinical course of patients with pancreatic cancer (PC) is inconclusive. This study aimed to determine whether or not the ABO blood type influences the long-term outcomes of PC in Japanese patients.Methods The medical records of Japanese patients with PC were reviewed. Data, including the age, sex, and outcomes, from the Ehime Pancreato-Cholangiology Study Group were analyzed.Results The mean age of the 406 patients was 71.0 +/- 10.5 years, and 220 (54.2%) were men. A total of 44.6%, 20.7%, 22.4%, and 12.3% had blood type A, B, O, and AB, respectively. The median survival time (MST) of patients with A alleles was shorter than that of patients with non-A alleles (p=0.048), especially among those who underwent resection (p=0.031). In contrast, no marked difference in the MST was noted among those who underwent chemotherapy and palliative care. Finally, a multivariate analysis confirmed A alleles as an independent factor associated with the long-term outcome of PC (p